Glycobia Overview
- Year Founded
-
2008
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$525K
- Investors
-
4
Glycobia General Information
Description
Developer of medical technologies designed to facilitate glycoengineering. The company's medical technologies engage in designing bacteria that produce novel and enhanced biotherapeutics to address unmet medical needs and it engages in developing glyco-engineered bacteria that are capable of attaching human or human-like sugars onto proteins, enabling biotechnology companies to produce authentic human glycoproteins in microbial cells for manufacturing and engineering of therapeutic proteins.
Contact Information
Website
www.glycobia.comCorporate Office
- 410 Weill Hall
- Cornell University
- Ithaca, NY 14853
- United States
Corporate Office
- 410 Weill Hall
- Cornell University
- Ithaca, NY 14853
- United States
Glycobia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 04-Jul-2019 | $525K | Completed | Startup | ||
| 4. Grant | 01-Jan-2015 | Completed | Startup | |||
| 3. Accelerator/Incubator | 01-Jan-2012 | Completed | Startup | |||
| 2. Grant | 01-Jan-2011 | $2.77M | $500K | Completed | Startup | |
| 1. Angel (individual) | 06-Oct-2010 | $500K | $500K | Completed | Startup |
Glycobia Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Glycobia Patents
Glycobia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190142921-A1 | Compositions and methods for the expression of eukaryotic oligosaccharides on bacterial outer membrane vesicles | Pending | 17-May-2016 | ||
| US-20140273103-A1 | Polysialic acid, blood group antigens and glycoprotein expression in prokaryotes | Inactive | 15-Mar-2013 | ||
| EP-2970942-A1 | Polysialic acid, blood group antigens and glycoprotein expression | Inactive | 15-Mar-2013 | ||
| US-20160032344-A1 | Polysialic acid, blood group antigens and glycoprotein expression in prokaryotes | Inactive | 15-Mar-2013 | ||
| CA-2906912-A1 | Polysialic acid, blood group antigens and glycoprotein expression | Inactive | 15-Mar-2013 | C12P21/005 |
Glycobia Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Cancer Institute | Government | |||
| National Institute of General Medical Sciences | Government | |||
| Kevin M. McGovern Family Center for Venture Development in the Life Sciences | Accelerator/Incubator | Minority | ||
| U.S. Department of Health and Human Services | Government |
Glycobia FAQs
-
When was Glycobia founded?
Glycobia was founded in 2008.
-
Where is Glycobia headquartered?
Glycobia is headquartered in Ithaca, NY.
-
What industry is Glycobia in?
Glycobia’s primary industry is Biotechnology.
-
Is Glycobia a private or public company?
Glycobia is a Private company.
-
What is Glycobia’s current revenue?
The current revenue for Glycobia is .
-
How much funding has Glycobia raised over time?
Glycobia has raised $500K.
-
Who are Glycobia’s investors?
National Cancer Institute, National Institute of General Medical Sciences, Kevin M. McGovern Family Center for Venture Development in the Life Sciences, and U.S. Department of Health and Human Services have invested in Glycobia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
